If DNDN can'reliably identify and quantify pure Provenge's benefit from the existing trial data, that might be a contributing factor to why they haven't made a partnership deal yet...
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.